roxi-ai
Roxi-AI is a life sciences analytics startup providing predictive, outcome-linked risk intelligence for biopharma asset evaluation and investment diligence, delivered via the ROXI 100 platform, ASK ROXI agent, diligence sprints and ROXI CONNECT marketplace to pharma, biotech, funds and analysts.
- Company typePrivate
- Founded2024
- HeadquartersYardley, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What roxi-ai does
Roxi-AI is a life sciences analytics company founded in 2024 and based in Yardley, United States, providing predictive risk analysis and research tools for biopharma asset evaluation and investment diligence. Its buyers are biopharma R&D, business development, medical and commercial teams; investment funds and research analysts (hedge funds, crossover funds, VC/PE, sell-side analysts); clinical development service providers (CROs); and investors and strategic partners. The company presents a two-person leadership team, Deepak Patil, MBBS, MBA, MS (Founder) and Lorraine Marchand, MBA (Partner/Contact), with no total headcount, incorporation details or funding disclosed.
The core technology is a longitudinal, outcomes-linked risk signal platform. A knowledge graph unifies fragmented clinical, scientific, regulatory and market evidence, time-stamps it and maps it to each asset's development path, feeding explainable predictive models trained and validated against historical approvals, halts and regulatory guidance. The proprietary ROXI 100 / Roxi-100 framework codifies 900+ weighted, time-stamped risk signals linked to outcomes and underpins ROXI INDEX (AAA-D graded asset risk assessment), BENCHMARK PRO (peer and industry benchmarking), SIMULATOR (scenario and portfolio stress testing), ASK ROXI (an AI research/diligence agent returning cited, explainable answers with governance controls) and ROXI CONNECT (a biopharma deal marketplace). Delivery is a hybrid of product and services: 72-hour diligence sprints ending in an investor-committee-ready memo, on-demand ticker/asset risk readouts, portfolio diagnostic and benchmarking engagements, and a competitive and catalyst radar, alongside advisory practices covering real world data strategy, R&D strategy, medical affairs, launch and commercial, and innovation acceleration. The company claims 92% directional accuracy at Phase-1 start on a blinded retrospective oncology cohort (n=64), with methods and limitations available only on request.
The business model spans four monetisation routes: authenticated platform and data subscription access through the web application at app.roxi-ai.com; professional services delivered as engagements (diligence sprints, equity research readouts, portfolio diagnostics); data monetisation of the ROXI 100, ROXI INDEX, BENCHMARK PRO and SIMULATOR modules; and marketplace economics on ROXI CONNECT matches. Go-to-market is demo-led and consultative, with calls to action to evaluate a company, assess a ticker, benchmark a portfolio or schedule a demo feeding an inquiry form segmented into Pharma & Biotech, Funds & Analysts, and Investors & Partners, supplemented by self-serve app access and website content demand generation tracked via Google Analytics. Pricing is quote-based and not publicly disclosed, and no revenue, ARR, funding, customer roster, incorporation details, patents or geographic footprint are disclosed in the source material.
roxi-ai firmographics
Firmographics- Name
- roxi-ai
- Legal name
- Roxi-AI
- Website
- https://roxi-ai.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Roxi-AI is a life sciences analytics startup providing predictive, outcome-linked risk intelligence for biopharma asset evaluation and investment diligence, delivered via the ROXI 100 platform, ASK ROXI agent, diligence sprints and ROXI CONNECT marketplace to pharma, biotech, funds and analysts.
- Ownership category
- akta.pro rank
roxi-ai industry classification
Industry- Product category
- Life Sciences Risk Intelligence Analytics
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (54169)
- SIC
- Services-Commercial Physical & Biological Research (8731), Investment Advice (6282)
- akta.pro industry
- AI/ML Platforms for Drug Discovery & Experiment OptimizationHealthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)Risk Management & Benefit–Risk (RMP/REMS/PSUR-PBRER)Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Pharmacovigilance & Medical Affairs ServicesRisk Quantification, Modeling & Stress TestingBusiness & Public Services/Professional Services (Legal, Accounting, Consulting)/Risk, Compliance & Governance Advisory
Keywords
Where roxi-ai is headquartered
LocationHeadquarters
- HQ city
- Yardley
- HQ country
- United States
- HQ region
- North America
Markets served
roxi-ai business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Platform/data subscription access: Authenticated access to the Roxi-AI web application and risk signal database (app.roxi-ai.com), implying a recurring subscription/paid-access model for the risk intelligence platform. Pricing is not publicly disclosed.
- Diligence sprints and professional advisory services: 72-hour focused diligence sprints on a company or asset, on-demand ticker/asset risk readouts with equity research reports, and portfolio diagnostic & benchmarking engagements delivered as engagements with IC-ready memos (project/service-based, one-time or repeat engagements).
- ROXI CONNECT marketplace: Biopharma deal marketplace connecting biopharma companies with investors; revenue likely transaction- or commission-based on matched deals, though no commercial terms are disclosed.
- Outcome-linked risk data and benchmarking products: Monetisation of the proprietary longitudinal, outcome-linked risk signals database and ROXI 100 / ROXI INDEX / BENCHMARK PRO / SIMULATOR tools (data monetisation), sold to funds, analysts and biopharma teams.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels3 records
roxi-ai product offering
Product offeringCore offering
Roxi-AI builds a longitudinal, outcomes-linked risk signals platform for biopharma: a knowledge graph that normalizes and time-stamps trial, regulatory, mechanistic, safety, competitive and commercial evidence, maps it to each asset's development path, and feeds explainable predictive models trained and validated against historical approvals, halts and regulatory guidance. The proprietary ROXI 100 framework codifies 900+ weighted, time-stamped risk signals linked to real outcomes, exposed through ROXI INDEX (AAA-D graded risk assessment), BENCHMARK PRO, SIMULATOR and the ASK ROXI AI research agent, and delivered as 72-hour diligence sprints, on-demand ticker/asset readouts, portfolio diagnostics, competitive/catalyst radar and advisory services.
Product overview
Roxi-AI is a platform-plus-modules offering rather than a single unified product: a proprietary longitudinal, outcomes-linked risk signals data foundation and knowledge graph of time-stamped clinical, regulatory, mechanistic, safety, competitive and commercial evidence underpins the core proprietary ROXI 100 100-point risk benchmarking framework, which in turn powers the ROXI INDEX (AAA-D graded asset risk assessment), BENCHMARK PRO (peer/industry benchmarking), SIMULATOR (scenario and portfolio stress testing) and ASK ROXI (AI diligence/research agent), alongside the ROXI CONNECT biopharma deal marketplace. These modules are delivered to funds, analysts and biopharma teams through service offerings — Diligence Sprint, Ticker/Asset Risk Readout, Portfolio Diagnostic & Benchmarking and Competitive & Catalyst Radar — and complementary advisory practices (Real World Data Strategy, R&D Strategy, Medical Affairs, Launch & Commercial, Innovation Acceleration).
Differentiator
Problem solved
Functional benefit
Brands
- ROXI 100: Proprietary 100-point risk benchmarking system used to evaluate biopharma assets and surface opportunities for de-risking development plans; also referenced as the 'Roxi-100' framework codifying 900+ weighted, time-stamped risk signals linked to outcomes.
- ROXI INDEX
- BENCHMARK PRO
- SIMULATOR
- ASK ROXI
- ROXI CONNECT
Products and services
- ROXI 100 Proprietary 100-point risk benchmarking system for biopharma assets and companies, built on 900+ weighted, time-stamped risk signals linked to real clinical and regulatory outcomes; used to evaluate assets and surface opportunities for de-risking development plans.
- ROXI INDEX Predictive assessment engine that rigorously evaluates biopharma assets using a comprehensive risk assessment graded on an AAA-D scale.
- BENCHMARK PRO Compares the risk profiles of biopharma assets against industry and peer benchmarks, supporting like-for-like competitive and peer profiling.
- SIMULATOR Simulates the impact of strategic design considerations and portfolio scenarios on the likelihood of clinical, regulatory and market success of an asset, used for portfolio and scenario stress tests.
- ASK ROXI (AI research agent) AI research copilot and diligence agent trained on life-sciences data, workflows and Roxi-AI risk signals; performs deep multi-step searches and returns cited, explainable answers with governance controls for R&D, medical and commercial teams and fund analysts.
- ROXI CONNECT Biopharma deal marketplace facilitating connections between biopharma companies and investors, used for deal sourcing and introductions.
- Diligence Sprint A 72-hour focused, explainable review of a company or asset using outcome-linked risk signals, finished with an investor-committee-ready memo; aimed at funds, analysts and biopharma teams making diligence decisions.
- Ticker / Asset Risk Readout On-demand signal snapshot with asset-level risk summaries, key drivers and peer comparators, built for public-market investment decisions; includes downloadable equity research reports and asset risk summaries for funds and analysts.
- Portfolio Diagnostic & Benchmarking Maps risks across a pipeline or portfolio, identifies fixable issues and benchmarks against peers to prioritise capital and work, with portfolio roll-ups of risk drivers and expected impact.
- Competitive & Catalyst Radar Continuous tracking of peer assets, milestones and risk shifts so teams identify inflection points before the market or the deal table, with near real-time updates as new evidence emerges.
- Real World Data Strategy Advisory service that unlocks value across disconnected in-house and third-party real world data sets for biopharma clients.
- R&D Strategy Advisory service focused on pipeline optimization and organisation-wide synergy enablement for early stage assets.
- Medical Affairs Medical affairs enablement advisory service that prepares the market for successful product launches.
- Launch & Commercial Advisory service covering pricing, go-to-market strategy and predictive market risk mitigation for biopharma launches.
- Innovation Acceleration Advisory service applying patient- and HCP-centric innovation models to drive cross-functional innovation.
Quantifiable outcome
- 92% directional accuracy at Phase-1 start on a blinded retrospective oncology cohort (n=64), with clear early separation between eventual approvals and failures
- +2 more outcomes
Companies that use roxi-ai
Customer profileSegments4 records
Ideal customer profiles4 records
roxi-ai technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature8 records
roxi-ai partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- NVIDIA (NVIDIA Inception Program)minorRoxi-AI is a member of the NVIDIA Inception Program, an accelerator for AI startups. The membership is displayed in the company's 'Programs & ecosystem' section on the Company page. It supports the company's AI-model and compute build-out for its biopharma risk intelligence platform. No specific deliverables, funding amount or dates are disclosed.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
roxi-ai competitors and assessment
Company assessmentDirect peers
- Trilytics: Applies machine learning to drug and device programs to estimate probability of technical success and inform pipeline prioritisation — the closest analog to Roxi-AI's ROXI INDEX graded asset-risk assessment and predictive success models.
- Citeline: Provides pharma R&D intelligence, clinical trial and pipeline data analytics used by biotech, pharma and investors for asset evaluation and competitive benchmarking, directly overlapping Roxi-AI's signal database and benchmarking products.
- Evaluate Pharma: Aggregates clinical, commercial and financial data into consensus forecasts and R&D risk/opportunity analysis for pipelines, serving the same biopharma BD and investor decision use cases as ROXI 100 and BENCHMARK PRO.
- BioWorld: Business intelligence on biotech pipelines, clinical trials, deals and company profiles with news, data and analysis; competes for the same budget and workflow in biopharma asset evaluation and investor diligence.
- AlphaSense: AI-driven market intelligence and diligence platform used by investment teams to research and answer questions with citations — the closest analog to ASK ROXI and to Roxi-AI's Funds & Analysts segment offering.
- DealForma: Pharma pipeline and market intelligence platform built for business development teams to evaluate and de-risk pipeline and licensing opportunities, overlapping Roxi-AI's use case of prioritising which assets to keep, kill or remediate.
- BioCentury: Biotech strategy intelligence, pipeline data and analyst reports aimed at biotech executives and investors, competing for the same decision-support spend as Roxi-AI's equity research reports and diligence sprints.
Emerging players
- Consensus: AI research platform that surfaces cited answers from primary research for analysts and investors; comparable in model (AI copilot over research corpus) though it is not specialised to biopharma asset risk.
Broad incumbents
- Certara: Provides quantitative biosimulation and R&D portfolio strategy software to pharma, with a broader scientific modelling portfolio that overlaps Roxi-AI's SIMULATOR scenario modelling for likelihood of success.
- IQVIA: Large-scale R&D and commercial data, analytics and advisory franchise spanning clinical data, real-world evidence and trial analytics; a broad incumbent whose data assets and client base overlap Roxi-AI's biopharma risk intelligence market.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights6 records
Customer concentration
roxi-ai social profiles
Digital presenceroxi-ai financial estimates
Financial estimateRevenue estimate
Valuation estimate
roxi-ai leadership team
Management profileNumber of profiles
Profiles2 records
roxi-ai funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
roxi-ai M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about roxi-ai
What does roxi-ai do?
Roxi-AI builds a longitudinal, outcomes-linked risk signals platform for biopharma: a knowledge graph that normalizes and time-stamps trial, regulatory, mechanistic, safety, competitive and commercial evidence, maps it to each asset's development path, and feeds explainable predictive models trained and validated against historical approvals, halts and regulatory guidance. The proprietary ROXI 100 framework codifies 900+ weighted, time-stamped risk signals linked to real outcomes, exposed through ROXI INDEX (AAA-D graded risk assessment), BENCHMARK PRO, SIMULATOR and the ASK ROXI AI research agent, and delivered as 72-hour diligence sprints, on-demand ticker/asset readouts, portfolio diagnostics, competitive/catalyst radar and advisory services.
Is roxi-ai a public or private company?
roxi-ai is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was roxi-ai founded?
roxi-ai was founded in 2024. It employs 1 to 10 people.
Where is roxi-ai based?
roxi-ai is headquartered in Yardley, United States, in the North America region.
How does roxi-ai make money?
Four revenue lines are on record. Platform/data subscription access are the primary driver. The others are diligence sprints and professional advisory services, ROXI CONNECT marketplace and outcome-linked risk data and benchmarking products.
Who are roxi-ai's main competitors?
Direct peers on record are Trilytics, Citeline, Evaluate Pharma, BioWorld, AlphaSense, DealForma and BioCentury. Consensus is listed as an emerging player. Broad incumbents are Certara and IQVIA.
Does roxi-ai have an API?
No public API is recorded for roxi-ai.
What industry is roxi-ai in?
roxi-ai's product category is Life Sciences Risk Intelligence Analytics. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGALAD, Risk Management & Benefit–Risk (RMP/REMS/PSUR-PBRER). Its NAICS code is 5417 and its SIC code is 8731.